Harvard Bioscience heads into its third-quarter report with something it has lacked for a while: a story the market believes. Shares have climbed about 35% since the last release while the S&P 500 slipped, a gap of roughly 38 percentage points. That rally rests on a revenue inflection and management's first upward guidance revision in the current sequence. The harder question now is whether that growth can start paying its way. Last quarter's sales beat came packaged with a gross-margin guidance cut and weaker cash flow, so the September quarter is a test of quality as much as quantity.
The headline estimate needs careful reading. Consensus calls for a loss of $0.65 per share, compared with a loss of $0.22 last quarter and a penny a year ago. That works out to a reported year-over-year decline of 6,400%, which looks dramatic mainly because the year-ago base was close to zero. Even so, a loss that large is hard to square with management's operating outlook. Q3 guidance implies mid-single-digit revenue growth against $20.6 million a year ago, which points to roughly $21.5 million, and the full-year adjusted EBITDA margin target of 6% to 10% was reaffirmed. The estimate may reflect charges or thin analyst coverage rather than a collapse in the business. Investors should therefore put more weight on revenue, adjusted margins and cash than on the bottom-line figure.
On revenue, the bar is modest, but the details matter. Second-quarter sales rose 11% to $22.7 million. China grew 29%, Asia-Pacific 24% and the Americas 13%, helped by contract research organizations and telemetry demand. Management lifted full-year growth guidance to 3% to 5% from 2% to 4%. To confirm that broadening demand, the company should show a few things. China should keep growing as the localized BTX electroporation line ships and more products gain certification. Fisher Scientific distribution should sustain double-digit growth. U.S. academic sales should firm, since management expects them to improve in the back half now that NIH budget money is flowing. New products reached 11% of revenue, up from 3% a year earlier, and holding or extending that share would suggest the commercial reorganization under the new sales chief is working. A slip back toward flat growth would undercut the claim that Q2 was a turning point rather than a single strong quarter.
Margins are where the narrative is most exposed. Adjusted gross margin fell to 57% from 59% in Q1 and about 60% in the prior fourth quarter. The cause was a mix shift toward lower-margin CMT products and China sales, and the full-year margin range was cut 100 basis points to 57% to 59%. Operating expenses also rose $1.2 million as salaries and merit increases were restored. A gross margin that stabilizes near the middle of the new range would ease concerns. Another step down would suggest the company is buying growth with profitability. Any sign of EBITDA margin moving above last quarter's 7.3% would show operating leverage finally arriving.
The balance sheet adds urgency. Cash fell to $6.5 million, net debt rose to $33.5 million, and first-half operating cash flow turned slightly negative because of inventory builds and higher interest costs. Those inventory builds now need to convert into sales and cash. Progress toward a sublease of the Holliston facility, which management did not expect before the fourth quarter or early next year, would also help.
Sentiment is only mildly bullish, which seems restrained given the stock's run. Shares at $8.67 sit in the upper part of a post-earnings range of $6.05 to $9.10, well above last quarter's $4.87 to $6.72 band, though not yet pressing the high. The rally has priced in the revenue recovery. What remains open is whether Harvard Bioscience can show that growth from China, CROs and new products comes with steady margins and improving cash generation. If it can, the improving narrative holds. If not, the guidance raise may look more like a trade-off than a turnaround.